Global Testosterone Cypionate Injection Market Size, Share and Trends Analysis Report, By Type (100 mg/ml and 200 mg/ml), By Injectable Testosterone (Enanthate, Cypionate, Propionate, and Testosterone Supension), By Application (Hospitals, Clinics, and Others), Forecast (2022-2028)

The global testosterone cypionate injection market is anticipated to grow at a CAGR of nearly 4.0% during the forecast period (2022-2028). Testosterone cypionate is an androgen used to treat low or absent testosterone. It has medical applications in the treatment of androgen deficiency (male hypogonadism), breast cancer, chronic obstructive pulmonary disease (COPD), endometriosis, hirsutism, breast disorders, oligospermia (low sperm count), hormone replacement therapy in transgender men, delayed puberty in boys, and osteoporosis.

Additionally, by type segment, 100 mg/ml testosterone cypionate injection is used for testosterone replacement therapy. The use of 100 mg/ml is increasing due to the rising awareness related to animal treatment and health. It comes in form of oil, which can be injected into cattle or any other animal for increasing muscle mass and production in animals such as cows, calves, pigs, and horses. Whereas by application segment, hospital dominates the market owing to the use of testosterone cypionate injection for replacement therapy for male hypogonadism, where it is given to men who do not produce enough testosterone naturally. It can also be used to help people with bone loss (osteoporosis) or growth failure in children with constitutional delay of growth and puberty, and for the palliative treatment of inoperable breast cancer with metastases in men.

Some major players in the market include Cipla Ltd., Novartis International AG, and Pfizer Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. In February 2021, Sun Pharmaceutical Industries Ltd. announced that the company is recalling 36,275 cartons of a drug used to treat low testosterone levels in the US market due to incorrect labeling.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Injectable Testosterone
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

• Competitive Landscape- Cipla Ltd., Novartis International AG, and Pfizer Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Testosterone Cypionate Injection Market Report by Segment

By Type

• 100 mg/ml
• 200 mg/ml

By Injectable Testosterone

• Enanthate
• Cypionate
• Propionate
• Testosterone Supension

By Application

• Hospitals
• Clinics
• Others

Global Testosterone Cypionate Injection Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa